Nanoviricides (NNVC) EBT (2010 - 2026)
Nanoviricides (NNVC) posted EBT of -$2.0 million for Q1 2026, up 9.09% sequentially from -$2.2 million in Q4 2025, and up 9.74% YoY from -$1.9 million in Q1 2025.
Nanoviricides (NNVC) EBT (2010 - 2026) Analysis & Trends
Nanoviricides has reported EBT for 17 years, with the latest figure at -$2.0 million in Q1 2026.
- Quarterly EBT rose 9.74% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 17.15% YoY) and the FY2025 annual result came in at -$9.6 million, down 12.29% from the prior year.
- EBT advanced to -$2.0 million in Q1 2026 per NNVC's latest filing, from -$2.2 million in the prior quarter.
- Over five years, EBT peaked at -$1.6 million in Q3 2022 and troughed at -$3.7 million in Q2 2023.
- A 5-year average of -$2.1 million and a median of -$2.0 million in 2026 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2025: EBT tumbled 106.54% in 2023, then jumped 43.28% in 2025.
- Over 5 years, EBT stood at -$1.7 million in 2022, then dropped by 25.95% to -$2.2 million in 2023, then gained by 6.32% to -$2.1 million in 2024, then dropped by 8.45% to -$2.2 million in 2025, then advanced by 9.09% to -$2.0 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$2.0 million, -$2.2 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | -2.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.03 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -2.12 Mn |
| Mar 31, 2025 | -2.25 Mn |
| Dec 31, 2024 | -2.06 Mn |
| Sep 30, 2024 | -3.17 Mn |
| Jun 30, 2024 | -2.39 Mn |
| Mar 31, 2024 | -1.91 Mn |
| Dec 31, 2023 | -2.20 Mn |
| Sep 30, 2023 | -1.97 Mn |
| Jun 30, 2023 | -3.68 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -1.75 Mn |
| Sep 30, 2022 | -1.57 Mn |
| Jun 30, 2022 | -1.78 Mn |
| Mar 31, 2022 | -1.79 Mn |
| Dec 31, 2021 | -1.92 Mn |
| Sep 30, 2021 | -2.61 Mn |
| Jun 30, 2021 | -2.07 Mn |